MTOR and medullary thyroid gland carcinoma: MTC-harboring RAS mutations showed a preferential activation of the PI3K/Akt/mTOR pathway, while RET-mutated MTC primarily involved the mitogen-activated protein kinase (MAPK) via [19]; thus, these different activation pathways may account for the different outcomes of the two molecular pathways.